Spark Therapeutics, which makes the therapy, today announced the whopping price tag. Called Luxturna, it was approved by the FDA in December, but Spark didn’t disclose the price at the time.
Now it has. And it’s a lot.
In a class of its own. The only approved gene therapy for an inherited type of blindness will cost $425,000 per eye—the most expensive single dose of a drug in the U.S. At $850,000 for both eyes, that would be more than 10 times the median net worth of an American family.
Who will benefit? The therapy is meant to restore eyesight in people who have a specific genetic mutation that causes degeneration of the retina. Spark hasn’t said how many people that is, but by our own estimates, it may be fewer than 30 patients a year.
Is it worth it? While the therapy does stop patients’ eyesight from getting worse and even restores some sight, it’s not a cure, and no one is sure how long the effects last. By contrast, a gene therapy on the market in Europe, called Strimvelis, effectively cures patients with a rare type of immune deficiency for the low, low price of $714,000.
Biotechnology and health
What to know about this autumn’s covid vaccines
New variants will pose a challenge, but early signs suggest the shots will still boost antibody responses.
A biotech company says it put dopamine-making cells into people’s brains
The experiment to treat Parkinson’s is a critical early test of stem cells’ potential to tackle serious disease.
Tiny faux organs could crack the mystery of menstruation
Researchers are using organoids to unlock one of the human body’s most mysterious—and miraculous—processes.
How AI can help us understand how cells work—and help cure diseases
A virtual cell modeling system, powered by AI, will lead to breakthroughs in our understanding of diseases, argue the cofounders of the Chan Zuckerberg Initiative.
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.